Market Performance
Indaptus Therapeutics (NASDAQ: INDP) closed the trading session on Friday, 23 October 2026 at a price of USD 3.18 per share, representing a +6.76 % increase during the 24‑hour period ending 08:44 PM Central Europe.
- Shares outstanding: 133.2 million
- Market capitalization: USD 485.3 million
- Volume traded in last 24 h: USD 1.7 million worth of shares
- Year‑to‑date change: -20.8 % since the end of the previous month
Key technical indicators:
- 200‑day simple moving average: USD 2.28
- 52‑week high: USD 5.96 (06 April 2026)
- 52‑week low: USD 0.92 (18 August 2026)
Corporate Actions
Indaptus filed three amendments to its Schedule 13D on 22 October 2026. The filings detail changes in the ownership percentages of three major holders—Sino Lion Ventures, Junyi Dai, and Yao Yun—after a private placement executed on 16 October. Each amendment confirms:
- A decrease of more than one percent in each holder’s stake due to the issuance of new shares.
- No additional purchases or sales of shares by these holders during the reporting period.
- Retention of voting and dispositive powers.
- Updated ownership percentages reflecting the company’s latest outstanding share count.
No other significant alterations to the ownership structure were reported.
Related Stock Movements
| Ticker | Change (24 h) | Current Price (USD) | Market Cap (USD m) |
|---|---|---|---|
| PHAT (Phathom) | –3.83 % | 5.55 | 568.7 |
| SHEN (Shenandoah Telecommunication) | +5.53 % | 10.42 | 570.3 |
| BLZE (Backblaze) | +1.85 % | 8.56 | 578.2 |
| CCXI (Churchill Capital) | –0.1 % | 10.27 | 576.5 |
| SBC (SBC Medical I) | +1.47 % | 5.30 | 569.8 |
Notable Developments Among Peer Companies
- Shenandoah Telecommunication: Board declared a cash dividend of $0.12 per share, payable 1 December 2026 to shareholders of record as of 2 November 2026. Dividend represents a ~9 % increase over the previous year.
- Churchill Capital Corp XI: Filed Form 425 reports for a proposed business combination with Agility Robotics. The transaction is expected to close in Q4 2026, enabling Agility Robotics to become a public company under the Nasdaq symbol AGLT. The combination includes plans for a new 50,000‑sq‑ft facility in Pittsburgh and standardization of the Digit 5 robot’s onboard computing with NVIDIA technology.
- SBC Medical I: Announced an internal research program to develop a DNA‑methylation test for estimating biological age. The initiative will be led by SBC AI Longevity Innovation and supported by the regenerative‑medicine expertise of the Waqoo Group. The test aims to provide a dynamic baseline for personalized health and lifestyle adjustments.
Company Overview
Indaptus Therapeutics, Inc. is a clinical‑stage biopharmaceutical company headquartered in New York, United States. The company focuses on developing proprietary platforms that harness bacteria’s natural ability to stimulate both innate and adaptive immune pathways. Indaptus is listed on the Nasdaq stock exchange and operates a global website at www.indaptusrx.com .
